Business context and reporting period
Filing identity discrepancy: The supplied filing is ARCA biopharma, Inc.’s Form 10-Q for the quarter ended September 30, 2017—not a filing for Oruka Therapeutics, Inc. Verify the issuer before relying on this summary.
ARCA was a clinical-stage biopharmaceutical company with no product revenue. Its lead candidate, Gencaro, was being studied in the Phase 2B GENETIC-AF trial for genetically selected patients with atrial fibrillation and heart failure with reduced ejection fraction. Enrollment of 267 patients was completed in August 2017.
Financial performance and position
Amounts are in millions of dollars except per-share figures. No revenue was reported; margins are therefore not meaningful.
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Research and development expense | $3.488 | $3.720 | $11.242 | $9.227 |
| General and administrative expense | $0.987 | $0.992 | $3.173 | $3.094 |
| Operating loss | $(4.475) | $(4.712) | $(14.415) | $(12.321) |
| Net loss | $(4.433) | $(4.659) | $(14.293) | $(12.200) |
| Net loss per share, basic and diluted | $(0.39) | $(0.51) | $(1.43) | $(1.35) |
| Net cash used in operating activities | Not stated quarterly | Not stated quarterly | $(13.276) | $(11.145) |
At September 30, 2017, cash and cash equivalents were $8.142 million and marketable securities were $7.809 million, totaling $15.951 million in liquid resources, versus $23.515 million at December 31, 2016. Current assets were $16.376 million and current liabilities $2.544 million. Total liabilities were $2.569 million; the filing reports no material conventional debt balance, but cash-flow disclosures include $0.256 million repayment of a vendor-financing arrangement. Stockholders’ equity was $14.352 million.
For the first nine months, investing activities provided $8.177 million, primarily from marketable-security maturities net of purchases; financing activities provided $5.840 million, reflecting approximately $6.1 million net proceeds from common-stock sales less vendor-finance repayments. Cash and cash equivalents increased $0.741 million, while cash, cash equivalents and marketable securities together declined $7.564 million.
Material changes versus comparable periods
- Q3 net loss narrowed to $4.433 million from $4.659 million; nine-month net loss widened to $14.293 million from $12.200 million.
- Nine-month R&D expense increased $2.015 million, chiefly due to GENETIC-AF clinical activity, personnel, CRO and European trial costs. Q3 R&D declined year over year, partly reflecting lower manufacturing-process development costs and timing of clinical-material production.
- Nine-month operating cash use increased $2.131 million year over year.
- Common shares outstanding rose to 11,750,744 from 9,082,366 at year-end 2016, primarily reflecting the at-the-market offering.
Outlook, risks and unusual items
- Management expected top-line GENETIC-AF results late in the first quarter of 2018. The DSMB recommended completing Phase 2B with no trial-design changes and reported no safety concerns; interim unblinded efficacy results were not disclosed. The recommendation did not transition the study to Phase 3.
- Management estimated available cash, cash equivalents and marketable securities would fund operations through the end of Q2 2018, but said additional capital or a strategic transaction would be needed for future operations and further development. The filing states substantial doubt exists about the company’s ability to continue as a going concern beyond one year after issuance of the financial statements.
- Failure to obtain financing or complete a strategic transaction could force ARCA to delay, reduce or discontinue development or operations. Further equity financing could dilute shareholders; debt financing could add senior obligations and restrictive covenants.
- In October 2017, after quarter-end, ARCA agreed to acquire Aeolus Pharmaceuticals’ minority interest in CPEC, a Gencaro rights-holder. ARCA said the transaction would reduce or eliminate certain potential milestone and royalty obligations and would not have a significant impact on annual financial statements.
- Other key risks include clinical efficacy and regulatory approval, companion-diagnostic approval and availability, dependence on CROs and manufacturers, Nasdaq listing requirements, and the need for a commercialization partner or substantial additional capital. Management reported disclosure controls were effective at a reasonable level of assurance and no material quarterly change in internal control over financial reporting.
Investor verification priorities
- Confirm the filing is for ARCA biopharma, Inc., not Oruka Therapeutics, Inc.
- Verify GENETIC-AF timing, final results and the implications of the DSMB’s recommendation.
- Assess cash runway against operating needs, the stated Q2 2018 funding horizon and the going-concern uncertainty.
- Check subsequent financing, strategic-transaction developments and the terms and effects of the Aeolus/CPEC transaction.
- Review dilution exposure, including remaining at-the-market capacity, warrants, options and other potential share issuance.